Matches in SemOpenAlex for { <https://semopenalex.org/work/W3111856198> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3111856198 endingPage "S715" @default.
- W3111856198 startingPage "S715" @default.
- W3111856198 abstract "To describe real-world treatment patterns and steroid usage as well as the steroid prescription alignment to clinical guidelines, prior to the use of thrombopoietin receptor agonists (TPO-RAs) in patients with immune thrombocytopenia (ITP) in Germany. The IMS® LRx prescription database was used to identify patients with at least one TPO-RA (romiplostim or eltrombopag) prescription between 7/2016 and 6/2019 in Germany. ITP treatments received prior to TPO-RA therapy were assessed. In total 3,553 patients were included in the analysis (2,752 eltrombopag, 801 romiplostim). Overall, 48% of patients were male and 57% of patients were >60 years when initiating TPO-RA. Oral steroids were the most commonly used therapy before TPO-RAs, in 2,289 of patients (64%; 69% eltrombopag, 48% romiplostim), followed by intravenous immunoglobulins (IVIg) in 249 of patients (7%; 6% eltrombopag, 10% romiplostim). Rituximab or other ITP treatments (e.g. azathioprine, mycophenolate mofetil, cyclophosphamide, dapsone) were rarely used before TPO-RAs. Rituximab was used in 2% of patients (1% eltrombopag, 4% romiplostim), other prior treatments in 5% of patients (5% eltrombopag, 6% romiplostim). Mean total days of steroid use prior to TPO-RAs was 169 days (median 105 days, maximum 540 days) and mean cumulative steroid (prednisolone equivalent) dose before TPO-RA therapy was 3,328 mg (median 2,522 mg, maximum 39,702 mg). Oral steroids were the most commonly used medication before TPO-RA therapy, reflecting their continued importance in the management of newly diagnosed ITP. However, treatment duration and cumulative steroid dose exceeded current guideline recommendations (ie from the American Society of Hematology 2019) and international consensus on ITP treatment. This over-use of steroids has the potential to lead to serious side effects and negatively impact on mental health, mood, sleep or weight gain for patients." @default.
- W3111856198 created "2020-12-21" @default.
- W3111856198 creator A5006327563 @default.
- W3111856198 creator A5026043098 @default.
- W3111856198 creator A5052749547 @default.
- W3111856198 creator A5063754167 @default.
- W3111856198 date "2020-12-01" @default.
- W3111856198 modified "2023-09-30" @default.
- W3111856198 title "PRO141 Treatment Patterns PRIOR to the Use of Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia in Germany" @default.
- W3111856198 doi "https://doi.org/10.1016/j.jval.2020.08.1877" @default.
- W3111856198 hasPublicationYear "2020" @default.
- W3111856198 type Work @default.
- W3111856198 sameAs 3111856198 @default.
- W3111856198 citedByCount "0" @default.
- W3111856198 crossrefType "journal-article" @default.
- W3111856198 hasAuthorship W3111856198A5006327563 @default.
- W3111856198 hasAuthorship W3111856198A5026043098 @default.
- W3111856198 hasAuthorship W3111856198A5052749547 @default.
- W3111856198 hasAuthorship W3111856198A5063754167 @default.
- W3111856198 hasBestOaLocation W31118561981 @default.
- W3111856198 hasConcept C109159458 @default.
- W3111856198 hasConcept C126322002 @default.
- W3111856198 hasConcept C2776760755 @default.
- W3111856198 hasConcept C2776915898 @default.
- W3111856198 hasConcept C2777863708 @default.
- W3111856198 hasConcept C2778713057 @default.
- W3111856198 hasConcept C2779134260 @default.
- W3111856198 hasConcept C2779338263 @default.
- W3111856198 hasConcept C2780588981 @default.
- W3111856198 hasConcept C2780653079 @default.
- W3111856198 hasConcept C28328180 @default.
- W3111856198 hasConcept C2993327898 @default.
- W3111856198 hasConcept C54355233 @default.
- W3111856198 hasConcept C71924100 @default.
- W3111856198 hasConcept C86803240 @default.
- W3111856198 hasConcept C89560881 @default.
- W3111856198 hasConcept C90924648 @default.
- W3111856198 hasConceptScore W3111856198C109159458 @default.
- W3111856198 hasConceptScore W3111856198C126322002 @default.
- W3111856198 hasConceptScore W3111856198C2776760755 @default.
- W3111856198 hasConceptScore W3111856198C2776915898 @default.
- W3111856198 hasConceptScore W3111856198C2777863708 @default.
- W3111856198 hasConceptScore W3111856198C2778713057 @default.
- W3111856198 hasConceptScore W3111856198C2779134260 @default.
- W3111856198 hasConceptScore W3111856198C2779338263 @default.
- W3111856198 hasConceptScore W3111856198C2780588981 @default.
- W3111856198 hasConceptScore W3111856198C2780653079 @default.
- W3111856198 hasConceptScore W3111856198C28328180 @default.
- W3111856198 hasConceptScore W3111856198C2993327898 @default.
- W3111856198 hasConceptScore W3111856198C54355233 @default.
- W3111856198 hasConceptScore W3111856198C71924100 @default.
- W3111856198 hasConceptScore W3111856198C86803240 @default.
- W3111856198 hasConceptScore W3111856198C89560881 @default.
- W3111856198 hasConceptScore W3111856198C90924648 @default.
- W3111856198 hasLocation W31118561981 @default.
- W3111856198 hasOpenAccess W3111856198 @default.
- W3111856198 hasPrimaryLocation W31118561981 @default.
- W3111856198 hasRelatedWork W10143852 @default.
- W3111856198 hasRelatedWork W2043512555 @default.
- W3111856198 hasRelatedWork W2397160689 @default.
- W3111856198 hasRelatedWork W2522216923 @default.
- W3111856198 hasRelatedWork W2885130125 @default.
- W3111856198 hasRelatedWork W2989530312 @default.
- W3111856198 hasRelatedWork W3028684527 @default.
- W3111856198 hasRelatedWork W4225386844 @default.
- W3111856198 hasRelatedWork W4281841986 @default.
- W3111856198 hasRelatedWork W74871909 @default.
- W3111856198 hasVolume "23" @default.
- W3111856198 isParatext "false" @default.
- W3111856198 isRetracted "false" @default.
- W3111856198 magId "3111856198" @default.
- W3111856198 workType "article" @default.